Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Telitacicept Pre-filled vs Freeze-dried Injection in Healthy Chinese Subjects
NCT06549959Phase 1Recruiting
- Sponsor
- RemeGen
- Start
- Aug 2024
- Primary completion
- Nov 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telitacicept in systemic lupus erythematosus (SLE) (2 arms), sponsored by RemeGen. Primary endpoints: Maximum Plasma Concentration at Day 57 and Area Under the Curve from time zero to infinity at Day 57. Started Aug 2024; status: recruiting.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06549959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549959.